Tocilizumab for the treatment of adult-onset Still’s disease-Reference-Cited by-同舟云学术

Tocilizumab for the treatment of adult-onset Still’s disease

Published:2019-03-22 Issue:4 Volume:19 Page:273-286
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Castañeda Santos¹,Martínez-Quintanilla Dolores¹,Martín-Varillas José L.²,García-Castañeda Noelia¹,Atienza-Mateo Belén²,González-Gay Miguel A.²³⁴

Affiliation:

1. Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Catedra de EPID-Futuro, Universidad Autónoma de Madrid (UAM), Madrid, Spain

2. Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

3. Department of Medicine, University of Cantabria, Santander, Spain

4. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1590334

Reference96 articles.

1. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France.

2. Epidemiology and outcome of adult‐onset Still's disease in Northern Norway

3. Adult-onset Still's disease: Advances in the treatment

4. A controlled study of the long-term prognosis of adult still's disease

5. Adult-onset still's disease

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus;Autoimmunity Reviews;2024-07

2. Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach;International Journal of Molecular Sciences;2024-05-10

3. Relationship between earlier introduction of tocilizumab and glucocorticoid-sparing effects on the acute phase of adult-onset Still’s disease;Scandinavian Journal of Rheumatology;2024-02-05

4. Successful Treatment of Recurrent Adult-Onset Still’s Disease with Tocilizumab: A Case Report and Literature Review;Clinical, Cosmetic and Investigational Dermatology;2023-11

5. A rare presentation of acute myocarditis as a manifestation of adult-onset Still’s disease: a case report;European Heart Journal - Case Reports;2023-10-25